Press Releases

SILVER SPRING, Md., Aug. 19, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia.

ITASCA, Ill., Aug. 19, 2019 /PRNewswire/ -- The National Safety Council is calling on Americans to observe International Overdose Awareness Day on Aug. 31 by

MADRID, Aug. 19, 2019 /PRNewswire/ -- PharmaMar (MSE: PHM) today announced that the FDA (Food and Drug Administration) agreed with PharmaMar's proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line SCLC.

FARMINGTON HILLS, Mich., Aug. 19, 2019 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute is the first cancer center in Mic

ATHENS, Ga., Aug. 19, 2019 /PRNewswire/ -- The following is included with permission from The Ties That Bind Us, a new interview series with musicians in recovery, by Steve Wildsmith: Addiction serves as a catalyst for the beautiful musical darkness of Nocturnal Blonde

NEW YORK, Aug. 19, 2019 /PRNewswire/ -- Today Fitz Frames unveiled a customized eyewear app specializing in children's glasses. Led by Founder Heidi Her

ENGLEWOOD, Colo., Aug. 19, 2019 /PRNewswire/ -- MedChain, Inc., an early stage company building globally compliant healthcare blockchain and decentralized applications (dApps) for electronic medical records (EMRs), announces the filing of its Provisional Patent Application related to methods of securely storing patient medical records utilizing Blockchain technolog

ROSEMONT, Ill., Aug. 19, 2019 /PRNewswire/ -- Most of the millions of people with varicose veins don't consider them a medical issue, unless they happen to be painful, achy or inflamed.

RONKONKOMA, N.Y., Aug. 19, 2019 /PRNewswire/ -- The Nature's Bounty Co., a global leader in health and wellness, today announced that Faissal Tahiri has joined the company as President, International, reporting to President and CEO Paul Sturman.

WEST LAFAYETTE, Ind., Aug. 19, 2019 /PRNewswire/ -- On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent imaging agents to improve cancer surgery, announced today that it has completed its Phase 2, multi-center, open-label clinical trial for OTL38 in the detection of lung cancer nodules in lung cancer pa